Revolutionizing Cancer Therapy with 3-Dimensional (3D) “Synthetic Peptide” Drugs
Pepto*ID is developing universally applicable 3D synthetic peptide therapeutics for difficult to treat cancers – overcoming key limitations of conventional drug types
Who We Are
By leveraging next-generation chemistry and biology, we engineer structurally defined molecules with enhanced stability, cell/tissue permeability, target selectivity, and drug-like properties.
Our platform is designed to enable new therapeutic approaches across challenging cancer targets, including tumors characterized by heterogeneity and drug resistance.
Our integrated discovery and development approach combines proprietary discovery platforms, lead optimization, and scalable synthesis to provide a streamlined path from hit discovery to candidate development, helping promising therapeutic concepts to advance efficiently through the development process.
Why Pepto*ID Is Unique
Pepto*ID combines flexible molecular design with our unique On-Bead Two-Color (OBTC) high-throughput cell screening technology to identify highly selective drug candidates across diverse therapeutic targets. Our integrated discovery and development platform can be tailored to the structural and chemical requirements of difficult-to-target therapeutic biomarkers, rather than being confined to a single molecular format or target class.
This flexibility also enables us to pursue new therapeutic strategies for both intrinsic and treatment-emergent drug resistance, including approaches directed toward shared cancer-associated biomarkers. Importantly, built-in drug-like properties such as stability, cell permeability, and bioavailability can be incorporated from the outset, reducing the need for expensive post-discovery optimization and helping streamline candidate development.
Our Platform Technology
Versatile 3D Synthetic Peptide Architecture Design
Flexible molecular design enables diverse 3D architectures and chemical functionalities tailored to different therapeutic targets.
LEARN MORE
Unique OBTC High-Throughput ‘Hit’ Identification
Our proprietary On-Bead Two-Color (OBTC) high-throughput screening technology enables rapid identification of highly selective ‘hit’ compounds for therapeutic targets of interest, while minimizing off-target interactions to reduce side effects.
Access to Challenging Targets
Our platform enables the design of structurally defined molecules capable of engaging diverse target classes, including shallow protein surfaces, tumor-associated lipids, and unconventional cell-surface drug-targets such as structural proteins.
Addressing Drug Resistance
Our platform supports multiple strategies to address drug resistance, including mutation-agnostic targeting, alternative tumor-associated targets, and discovery directly in resistant disease states.
Stability and Bioavailability Optimization
Specialized building blocks and structural features enable drug-like properties to be automatically built into the molecular design, supporting enhanced stability, cell/tissue permeability, bioavailability, and favorable PK/PD properties.
OUR PIPELINE
PID-01
A mutation-agnostic pan-KRAS lead candidate designed for broad KRAS targeting across multiple variants, with potent anticancer activity demonstrated in NSCLC and PDAC models, including those resistant to existing KRAS-targeted therapies.
PID-02
A next-generation therapeutic targeting cancer stem cell-associated cell-surface plectin, an unconventional cell surface biomarker linked to metastatic disease, with potential for combination therapy for difficult to treat advanced cancers.
PID-03
A 3D synthetic peptide therapeutic targeting externalized phosphatidylserine (PS) lipid, extending beyond conventional protein targets with broad potential across cancer types.
Discovery & Research
Our ongoing discovery programs focus on novel cancer-associated targets, resistant disease states, and underserved tumor phenotypes
Future Innovation
We aim to integrate AI-driven molecular design and data-driven analysis into our 3D synthetic peptide and peptidomimetic platform to advance next-generation therapeutic discovery.
OUR TEAM
TANU CHATTERJI, PhD
Director, Startup Development and UH Technology Bridge Incubator
ALOE BLACC
Grammy-nominated, multi-platinum, singer/songwriter, known for major hits such as “I Need A Dollar”, “The Man”, and “Wake Me Up”, pledged early in his career to use his music for positive social transformation.
GOMIKA UDUGAMASOORIYA, PhD
Professor Udugamasooriya, affiliated with the University of Houston and the MD
Anderson Cancer Center, holds a number of patents and is a Senior Member of the
National Academy of Inventors (NAI) in United States